Have your properties as NFT - Work with data for analysis - Use MAP token to transact - Share what you want to everyone - Explore the world and buy, sell or rent" ...

Touting what’s been so far the “cleanest safety profile that’s been presented with genetic medicine in the eye,” deemed “a game changer for this field,” 4D Molecular Therapeutics Inc. CEO David Kirn ...

Monday, 4D Molecular Therapeutics FDMT released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (wet AMD) patients.

4D Molecular Therapeutics Inc (NASDAQ: FDMT) announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 trials for Fabry disease cardiomyopathy.

Wednesday, 4D Molecular Therapeutics, Inc.(NASDAQ:FDMT) unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial. The trial evaluates intravitreal 4D ...

EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for ...

4D Molecular Therapeutics (NASDAQ:FDMT) shares surged over 60% premarket after the company reported positive interim data for its eye disease drug, 4D-150. Data consists of 24-week results from a ...

4D Molecular Therapeutics FDMT stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

4D Molecular Therapeutics (NASDAQ:FDMT) has plunged 31% in Thursday morning trading following the release of interim phase 1/2 data on wet age-related macular degeneration (AMD) asset 4D-150.

(Reuters) - Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy. The stock hit an over ...